Acuson is realizing the benefits from its release last year of the Aspen and Sequoia ultrasound scanners. The Mountain View, CA-based vendor reported record revenues for the first quarter of 1997 (end-March) of $107.6 million, a 27% jump over the $84.8
Acuson is realizing the benefits from its release last year of the Aspen and Sequoia ultrasound scanners. The Mountain View, CA-based vendor reported record revenues for the first quarter of 1997 (end-March) of $107.6 million, a 27% jump over the $84.8 million reported in first quarter 1996. Net income totaled $5.8 million, compared with $1.3 million for the same period in 1996. Earnings per share were above analysts' expectations for the quarter.
It was the first quarter for Acuson that exceeded $100 million in revenues and represented the third straight record quarter for sales. Acuson executives credited the success of the Sequoia and Aspen platforms and a strong worldwide ultrasound market as key factors behind the prosperous financial results.
Acuson's revenues surpassed those of arch rival ATL, which reported first-quarter sales of $100.1 million. ATL has usually reported higher revenues than Acuson since the Bothell, WA, company's acquisition of Interspec in 1994.
Acuson also benefited from two large orders in the first quarter. Diagnostic Health Services purchased 22 scanners, primarily Aspen systems, and Henry Ford Hospital in Detroit acquired nine Sequoia C256 echocardiography units (SCAN 4/30/97). Some revenue from those sales will also be realized in the second quarter, according to Stephen Johnson, CFO.
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Study Shows Enhanced Diagnosis of Coronary Artery Stenosis with Photon-Counting CTA
July 10th 2025In a new study comparing standard resolution and ultra-high resolution modes for patients undergoing coronary CTA with photon-counting detector CT, researchers found that segment-level sensitivity and accuracy rates for diagnosing coronary artery stenosis were consistently > 89.6 percent.
FDA Expands Approval of MRI-Guided Ultrasound Treatment for Patients with Parkinson’s Disease
July 9th 2025For patients with advanced Parkinson’s disease, the expanded FDA approval of the Exablate Neuro platform allows for the use of MRI-guided focused ultrasound in performing staged bilateral pallidothalamic tractotomy.